On Friday, Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) was -6.07% drop from the session before settling in for the closing price of $47.64. A 52-week range for RARE has been $37.02 – $60.37.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 63.06% over the last five years. When this article was written, the company’s average yearly earnings per share was at 24.07%. With a float of $86.53 million, this company’s outstanding shares have now reached $92.34 million.
The firm has a total of 1276 workers. Let’s measure their productivity. In terms of profitability, gross margin is 82.86%, operating margin of -102.49%, and the pretax margin is -107.33%.
Ultragenyx Pharmaceutical Inc (RARE) Breakdown of a Key Holders of the stock
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Ultragenyx Pharmaceutical Inc stocks. The insider ownership of Ultragenyx Pharmaceutical Inc is 6.46%, while institutional ownership is 95.03%. The most recent insider transaction that took place on Oct 10 ’24, was worth 393,853. In this transaction Chief Financial Officer of this company sold 7,465 shares at a rate of $52.76, taking the stock ownership to the 92,301 shares. Before that another transaction happened on Sep 03 ’24, when Company’s President & CEO sold 20,000 for $55.85, making the entire transaction worth $1,117,000. This insider now owns 2,223,985 shares in total.
Ultragenyx Pharmaceutical Inc (RARE) Recent Fiscal highlights
According to the Wall Street analysts, stocks earnings will be around 24.07% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 37.90% during the next five years compared to -15.75% drop over the previous five years of trading.
Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) Trading Performance Indicators
You can see what Ultragenyx Pharmaceutical Inc (RARE) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 2.65. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 7.43.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -6.46, a number that is poised to hit -1.35 in the next quarter and is forecasted to reach -5.11 in one year’s time.
Technical Analysis of Ultragenyx Pharmaceutical Inc (RARE)
Analysing the last 5-days average volume posted by the [Ultragenyx Pharmaceutical Inc, RARE], we can find that recorded value of 0.88 million was better than the volume posted last year of 0.79 million. As of the previous 9 days, the stock’s Stochastic %D was 6.82%. Additionally, its Average True Range was 1.99.
During the past 100 days, Ultragenyx Pharmaceutical Inc’s (RARE) raw stochastic average was set at 24.63%, which indicates a significant increase from 2.46% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 37.90% in the past 14 days, which was lower than the 38.03% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $54.25, while its 200-day Moving Average is $48.10. Now, the first resistance to watch is $47.06. This is followed by the second major resistance level at $49.38. The third major resistance level sits at $50.64. If the price goes on to break the first support level at $43.48, it is likely to go to the next support level at $42.22. Now, if the price goes above the second support level, the third support stands at $39.90.
Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) Key Stats
There are 92,344K outstanding shares of the company, which has a market capitalization of 3.88 billion. As of now, sales total 434,250 K while income totals -606,640 K. Its latest quarter income was 139,490 K while its last quarter net income were -133,520 K.
